Dnatrix Incis A Biotechnology Company Focused On Developing Oncolytic Virus Driven Immunotherapies For Aggressive Cancersfounded In 2005 And Headquartered In Houstontxthe Company Has Raised A Total Of $38 88 Million In Fundingits Key Founders Include Renowned Physicians And Scientists From The Ucsf Helen Diller Comprehensive Cancer Center And Md Anderson Cancer Centerin 2012Dnatrix Merged With Vectorlogicsenhancing Its Expertise In Cancer Treatment The Company Specializes In Modified Adenoviruses That Selectively Target And Destroy Cancer Cells While Preserving Healthy Tissueits Lead Productdnx 2401Is Designed For Glioblastoma And Other Solid Tumorsutilizing Mechanisms That Activate The Immune Systemdnatrix Is Advancing Several Therapies In Its Pipelineincluding Dnx 2465 For Solid Tumors And Interferon Gamma Gene Therapy Targeting Gliomathe Company Has Received Eu Orphan Medicine And Ema Prime Designation For Its Glioblastoma Therapies And Is Actively Conducting Clinical Trials For Various Cancersdnatrix Aims To Expand Its Applications To Additional Cancer Typescomplementing Existing Treatments
